利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

26 条记录 (耗时 0.021 秒)

    ASSAY FOR THE DIAGNOSIS OF DEMENTIA
    1.
    发明申请
    ASSAY FOR THE DIAGNOSIS OF DEMENTIA 无效
    测定DEMENTIA诊断

    公开(公告)号：US20030096227A1

    公开(公告)日：2003-05-22

    申请号：US09043781

    申请日：1998-06-18

    发明人： MEIR SHINITZKY ,  MICHAEL DECKMANN

    IPC分类号： C12Q001/68 ,  G01N033/567 ,  G01N033/53 ,  G01N033/555

    CPC分类号： G01N33/6896 ,  G01N33/564 ,  G01N33/56972 ,  G01N2800/2814 ,  G01N2800/2821

    摘要： An assay for the diagnosis of multi-infarct dementia and dementia of the Alzheimer type in an individual is provided. It comprises the steps of obtaining a sample from said individual being a blood sample, a platelet-containing fragment thereof, or a fragment containing platelet associated antibodies (PAA) detached from the platelets, and then determining the level of a platelet associated antibody against a 75 kD platelet-protein in said sample. A level higher than that of a control sample indicates that said individual has a high likelihood of having multi-infarct dementia or dementia of the Alzheimer type.

    摘要翻译： 提供了用于诊断个体中多发性梗塞性痴呆和阿尔茨海默氏痴呆症的测定法。 它包括以下步骤：从所述个体获得来自血液样品的样品，其含血小板片段或含有与血小板分离的血小板相关抗体（PAA）的片段，然后测定抗血小板相关抗体的水平 所述样品中的75kD血小板蛋白。 高于对照样品的水平表明所述个体具有多发性梗塞性痴呆或阿尔茨海默氏型痴呆的可能性。

    TUMORICIDAL T LYMPHOCYTES
    3.
    发明申请
    TUMORICIDAL T LYMPHOCYTES 失效

    公开(公告)号：US20020039569A1

    公开(公告)日：2002-04-04

    申请号：US08513865

    申请日：1995-12-04

    发明人： HERBERT JUNGFER ,  HEINRICH BARCHET ,  WINFRED ALBERT ,  ULRICH WEIDLE

    IPC分类号： G01N033/53 ,  G01N033/555 ,  G01N033/567 ,  C12N005/06 ,  C12N005/08

    CPC分类号： A61K39/0011 ,  A61K2039/5158

    摘要： The present invention concerns a mammalian cell line which when co-cultured with lymphocytes during which allogenic stimulation is avoided activates lymphocytes fo form tumoricidal cells, a process for the production of tumoricidal T lymphocytes by co-culturing lymphocytes with this cell line, the tumoricidal T lymphocytes obtained by means of this process and the use of the cells according to the present invention for the production of a therapeutic agent which can be used in tumour therapy.

    摘要翻译： 本发明涉及哺乳动物细胞系，当与避免同种异体刺激的淋巴细胞共同培养时，可激活形成杀肿瘤细胞的淋巴细胞，通过与该细胞系共培养淋巴细胞产生杀肿瘤T淋巴细胞的方法，杀肿瘤T 通过该方法获得的淋巴细胞和根据本发明的细胞用于生产可用于肿瘤治疗的治疗剂。

    Molecular marker
    5.
    发明申请
    Molecular marker 失效
    分子标记

    公开(公告)号：US20040214349A1

    公开(公告)日：2004-10-28

    申请号：US10699035

    申请日：2003-10-31

    发明人： John Francis Bateman ,  David James Fitzgerald

    IPC分类号： C07K014/775 ,  C07H021/04 ,  C12P021/04 ,  G01N033/555

    CPC分类号： A61K38/36 ,  A01K2217/05 ,  A01K2217/075 ,  C07H21/04 ,  C07K14/47 ,  C07K14/78 ,  C07K16/18 ,  C12Q1/6883 ,  G01N2333/755 ,  G01N2333/78

    摘要： The present invention relates generally to a molecular marker of the integrity of the extracellular matrix in an animal including a human subject. More particularly, the present invention provides a molecular marker of cartilage integrity. The identification of the molecular marker in circulatory or tissue fluid is indicative of disrepair of the extracellular matrix and in particular cartilage such as caused or facilitated by trauma or a degenerative disease or other condition, for example, arthritis or autoimmunity. The molecular marker is preferably in the form of a glycoprotein but the instant invention extends to genetic sequences encoding the polypeptide portion of the glycoprotein. Expression analysis of such genetic sequences provides predictive utility in detecting normal or abnormal extracellular matrix development. The identification of the molecular marker of the present invention enables the development of a range of diagnostic and therapeutic agents for degeneration of extracellular matrix or the poor development of the matrix at the fetal and postnatal stages including testing for mutations in the gene sequence in human disease such as but not limited to cartilage disease or arthritis. In a most preferred embodiment, the molecular marker is referred to herein as nullWARPnull for von Willebrand Factor A-Related Protein. The corresponding genetic form of WARP is referred to herein as nullWARPnull.

    摘要翻译： 本发明一般涉及包括人类受试者的动物中细胞外基质完整性的分子标记。 更具体地，本发明提供了软骨完整性的分子标记。 循环或组织液中的分子标记物的鉴定指示细胞外基质的失修，特别是软骨，例如由创伤或退行性疾病或其他病症引起或促进的软骨，例如关节炎或自身免疫。 分子标记优选为糖蛋白的形式，但本发明延伸至编码糖蛋白多肽部分的遗传序列。 这种遗传序列的表达分析提供了检测正常或异常细胞外基质发育的预测效用。 本发明的分子标记物的鉴定使得能够开发一系列用于细胞外基质变性的诊断和治疗剂或胎儿和出生后阶段的基质发育不良，包括测试人类疾病基因序列中的突变 例如但不限于软骨疾病或关节炎。 在最优选的实施方案中，分子标记在本文中称为von Willebrand因子A相关蛋白的“WARP”。 WARP的相应遗传形式在本文称为“WARP”。

    METHOD AND COMPOSITIONS FOR OBTAINING MATURE DENDRITIC CELLS
    6.
    发明申请
    METHOD AND COMPOSITIONS FOR OBTAINING MATURE DENDRITIC CELLS 失效
    用于获得成熟细胞的方法和组合物

    公开(公告)号：US20030096314A1

    公开(公告)日：2003-05-22

    申请号：US08600483

    申请日：1996-02-12

    发明人： RALPH M. STEINMAN ,  NINA BHARDWAJ ,  GEROLD SCHULER

    IPC分类号： G01N033/53 ,  G01N033/567 ,  G01N033/555 ,  G01N033/48 ,  G01N033/50

    CPC分类号： C12N5/0639 ,  A61K38/00 ,  A61K2039/5154 ,  C12N2501/22 ,  C12N2501/23 ,  C12N2502/11

    摘要： We describe an improved method for generating sizable numbers of mature dendritic cells from nonproliferating progenitors in human blood. The first step or nullprimingnull phase is a culture of T cell depleted mononuclear cells in medium supplemented with GM-CSF and IL-4 to produce immature dendritic cells. The second step or nulldifferentiationnull phase requires the exposure to dendritic cell maturation factor such as monocyte conditioned medium. Using this two-step approach, substantial yields are obtained. The dendritic cells derive from this method have all the features of mature cells. They include a stellate cell shape, nonadherence to plastic, and very strong T cell stimulatory activity. The mature dendritic cells produced according to this invention are useful for activating T cells.

    摘要翻译： 我们描述了一种用于从人血液中的非增殖祖细胞产生大量成熟树突状细胞的改进方法。 第一步或“引发”阶段是补充有GM-CSF和IL-4的培养基中产生未成熟树突状细胞的T细胞耗尽的单核细胞的培养物。 第二步或“分化”阶段需要暴露于树突状细胞成熟因子如单核细胞条件培养基。 使用这种两步法，可以获得显着的产量。 这种方法得到的树突状细胞具有成熟细胞的所有特征。 它们包括星状细胞形状，不粘附于塑料，以及非常强的T细胞刺激活性。 根据本发明产生的成熟树突状细胞可用于激活T细胞。

    METHOD FOR DETECTING T CELL RESPONSE TO SPECIFIC ANTIGENS IN WHOLE BLOOD
    8.
    发明申请
    METHOD FOR DETECTING T CELL RESPONSE TO SPECIFIC ANTIGENS IN WHOLE BLOOD 失效
    用于检测T细胞对全血中特异性抗原的反应的方法

    公开(公告)号：US20010006789A1

    公开(公告)日：2001-07-05

    申请号：US08803702

    申请日：1997-02-21

    发明人： VERNON C. MAINO ,  MARIA SUNI

    IPC分类号： G01N033/53 ,  G01N033/567 ,  G01N033/555

    CPC分类号： G01N33/56972

    摘要： This invention comprises a novel approach to the assessment of antigen-specific T cells that quantitates and characterizes these cells with unprecedented clarity, and importantly, because it is performed in whole blood, is amenable to routine use in the clinical immunology laboratory. The methodology offers an improved flow cytometric intracellular cytokine assay in whole blood that can simultaneously measure multiple T cell subsets expressing multiple cytokines from a single whole blood culture. Evaluation of whole blood antigen specific cytokine responses has the important advantage of assessing T cell activation in the presence of ALL types of MHC autologous antigen presenting cells present in the native sample. It also has the advantage of enabling a culture system (whole blood) which can reflect effects of systemic environments (i.e. drug augmentation or suppression) on T cell responses to specific stimuli including antigen, by either culturing in the presence of such drug or analyzing the blood of a human or animal receiving such drug.

    摘要翻译： 本发明包括以前所未有的清晰度定量和表征这些细胞的抗原特异性T细胞的评估的新方法，并且重要的是因为其在全血中进行，可适用于临床免疫学实验室中常规使用。 该方法提供了全血中改进的流式细胞计数细胞因子测定法，其可以同时测量来自单一全血培养物中表达多种细胞因子的多种T细胞亚群。 全血抗原特异性细胞因子反应的评估在存在于天然样品中的ALL类型的MHC自体抗原呈递细胞的存在下具有评估T细胞活化的重要优点。 它还具有使得能够反映系统性环境（即药物增加或抑制）对T细胞对特定刺激（包括抗原）的反应的影响的培养系统（全血）的优点，通过在这种药物存在下培养或分析 接受这种药物的人或动物的血液。

    Method, assay, and kit for quantifying HIV protease inhibitors
    9.
    发明申请
    Method, assay, and kit for quantifying HIV protease inhibitors 失效
    用于定量HIV蛋白酶抑制剂的方法，测定和试剂盒

    公开(公告)号：US20040081957A1

    公开(公告)日：2004-04-29

    申请号：US10284040

    申请日：2002-10-29

    发明人： Herbert von der Eltz ,  Lili Arabshahi ,  Haijuan Li ,  Erasmus Huber

    IPC分类号： C12Q001/70 ,  G01N033/53 ,  G01N033/567 ,  G01N033/555 ,  C12Q001/02

    CPC分类号： G01N33/573 ,  G01N33/56988 ,  G01N2333/81 ,  G01N2333/948 ,  Y10S435/81

    摘要： A method for quantifying an HIV protease inhibitor in a sample includes combining HIV protease, a conjugate comprising an HIV protease inhibitor analog, and a sample suspected of containing an HIV protease inhibitor. The HIV protease and the conjugate are capable of forming a detectable complex. The method also includes measuring the amount of the detectable complex, and relating the amount of the detectable complex to a concentration of the HIV protease inhibitor in the sample.

    摘要翻译： 用于定量样品中的HIV蛋白酶抑制剂的方法包括将HIV蛋白酶，包含HIV蛋白酶抑制剂类似物的缀合物和怀疑含有HIV蛋白酶抑制剂的样品相结合。 HIV蛋白酶和缀合物能够形成可检测的复合物。 该方法还包括测量可检测复合物的量，并将可检测复合物的量与样品中HIV蛋白酶抑制剂的浓度相关联。

    ANTIBODIES SPECIFIC FOR OSTEOPROTEGERIN BINDING PROTEINS AND METHOD OF USE
    10.
    发明申请
    ANTIBODIES SPECIFIC FOR OSTEOPROTEGERIN BINDING PROTEINS AND METHOD OF USE 无效
    用于骨质疏松蛋白结合蛋白的特异性抗体及其使用方法

    公开(公告)号：US20030104485A1

    公开(公告)日：2003-06-05

    申请号：US09079569

    申请日：1998-05-14

    发明人： WILLIAM J. BOYLE

    IPC分类号： G01N033/53 ,  G01N033/567 ,  G01N033/555 ,  C07H021/04 ,  C12P021/02 ,  C12N005/06 ,  C07K014/705 ,  C07K016/28

    CPC分类号： C07K14/70575 ,  A61K38/00 ,  C07K14/70578

    摘要： A novel polypeptide, oseteoprotegerin binding protein, involved in osteolcast maturation has been identified based upon its affinity for osteoprotegerin. Nucleic acid sequences encoding the polypeptide, or a fragment, analog or derivative thereof, vectors and host cells for production, methods of preparing osteoprotegerin binding protein, and binding assays are also described. Compositions and methods for the treatment of bone diseases such as osteoporosis, bone loss due to arthritis or metastasis, hypercalcemia, and Paget's disease are also provided.

    摘要翻译： 已经基于其对骨保护素的亲和力，鉴定参与骨转播成熟的新型多肽，蛋白整合蛋白结合蛋白。 还描述了编码多肽或其片段，类似物或衍生物的核酸序列，用于产生的载体和宿主细胞，制备骨保护蛋白结合蛋白的方法和结合测定。 还提供了用于治疗骨质疏松症，由于关节炎或转移引起的骨丢失，高钙血症和佩吉特氏病等骨疾病的组合物和方法。